Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | compounds already reach it: glpg-0974 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 378 | 0.76 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6536
Sealed predictions
- FFAR2 in dopamine neurons, braak-0.41 (p 0.272) → -0.44 (p 0.232)receipt 6543
Swarm cases
receipt 6543: FFAR2 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.142, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.33 (p 0.188, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.043, n 18). not the mix.
- skeptic
- leave-one-out range -0.51 to -0.28, sign flips 0; without severely affected donors -0.36 (p 0.142, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FFAR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts